000			01688nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aMalignant Mesothelioma
546			_aEnglish[eng]
650			_awell-differentiated papillary mesothelioma||WDPM||malignant mesothelioma||DNA sequencing||mutation||mesothelioma||tumor suppressor||targeted therapy||immunotherapy||biomarkers||proteomics||macrophage-capping protein||fatty acid-binding protein||laminin subunit beta-2||selenium-binding protein 1||carcinogenesis||malignant pleural mesothelioma||asbestos exposure||DNA methylation||lymphocyte-to-monocyte ratio||epigenome-wide analysis||survival analysis||metabolomics||radiotherapy||cancers||inflammation||infiltrating immune cells||prognostic biomarker||predictive biomarker||immune therapy||VATS||extrapleural pneumonectomy||pleurectomy decortication||therapy response||survival||FDG||PET-CT||mesothelium||oxidative stress||redox-sensitive factors||asbestos||carbon nanotubes||protein-protein interactions||systems biology||network analysis||drug repurposing||pleural mesothelioma||gene expression||immunogenicity||sarcomatoid||epithelioid||first line||meta-analysis||systematic review||MPM||lurbinectedin||DNA damage response||histotype||Hippo pathway||NF2||BAP1||CDKN2A||PTCH1||SETD2||MTAP||liquid biopsies||circulating tumor DNA||plasma||cancer-specific mutations||genomics||cancer biomarkers||tumor microenvironment||tumor-associated macrophages||dendritic cells||immunohistochemistry||interaction analysis||pleural effusion||n/a
700			_aL. Pouliquen, Daniel||Kopecka, Joanna
856			_uhttps://mdpi.com/books/pdfview/book/4656
942			_cEB
999			_c33795 _d33795